Effectiveness of vildagliptin as add‐on to metformin monotherapy among uncontrolled type 2 diabetes mellitus patients in a real‐world setting

Publisher： John Wiley & Sons Inc

E-ISSN： 1753-0407|10|1|68-72

ISSN： 1753-0393

Source： JOURNAL OF DIABETES, Vol.10, Iss.1, 2018-01, pp. : 68-72

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany

By Göke R.   Gruenberger J. B.   Bader G.   Dworak M.  

Current Medical Research and Opinion, Vol. 30, Iss. 5, 2014-05 ,pp. : 785-789

Informa Healthcare

Access to resources Recommend Favorite

Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan

By Hanif W.  

Current Medical Research and Opinion, Vol. 29, Iss. 7, 2013-07 ,pp. : 807-811

Informa Healthcare

Access to resources Recommend Favorite

The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus

By  

DIABETIC MEDICINE, Vol. 32, Iss. 7, 2015-07 ,pp. : 890-898

John Wiley & Sons Inc

Access to resources Recommend Favorite

Empagliflozin as add‐on to metformin in people with Type 2 diabetes

By  

DIABETIC MEDICINE, Vol. 32, Iss. 12, 2015-12 ,pp. : 1555-1567

John Wiley & Sons Inc

Access to resources Recommend Favorite

Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes*

By He Yan-Ling   Sabo Ron   Picard Franck   Wang Yibin   Herron Jerry   Ligueros-Saylan Monica   Dole William P.  

Current Medical Research and Opinion, Vol. 25, Iss. 5, 2009-05 ,pp. : 1265-1272

Informa Healthcare

Access to resources Recommend Favorite